Juno Therapeutics

View All

Delveinsight
Snippet: M&A activities of big pharma’s will fuel CAR-T cell therapy

Gilead Sciences Inc. bought Kite Pharma (USD 11.9 Billion) while Celgene took over Juno Therapeutics (USD 9 Billion) to make the greatest speculation into this rising subject over the recent one year. While experts hope that each individual CAR-T therapies will yield sales of USD 1 billion, the investing companies...

Find More

transthyretin amyloidosis
Notizia

Pharma giant Celgene finally confirms USD 9 billion Juno Therapeutics buyout Celgene has finally confirmed the week-long rumor of buying Juno Therapeutics for a deal worth around USD 9 billion boosting its Grip in CAR-T therapy domain. A major reason for this buyout is Juno’s lead CAR-T drug candidate JCAR017 that ...

Find More